Beyond Genomics to Chair Panel of Experts at BIO 2003; BG Leads Panel on the Application of Systems Biology in Drug Discovery.Business Editors/Health/Medical Writers BIO 2003 Annual Convention BIOWIRE2K WALTHAM, Mass.--(BUSINESS WIRE)--June 19, 2003 Beyond Genomics, Inc. (BG) announced today that it will lead a Drug Discovery and Development session entitled Systems Biology Systems biology, a field of study in the biosciences, focuses on the systematic study of complex interactions in biological systems. Particularly from 2000 onwards, the term is used widely in the biosciences, and in a variety of contexts. : Integration into Drug Discovery at the Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
"Beyond Genomics is pleased to have the opportunity to assemble and lead such a distinguished panel of experts. The panel will highlight the diverse applications of Systems Biology for drug discovery, and create increased interest in this approach among researchers," said N. Stephen Ober, MD, President of Beyond Genomics. "We have been most fortunate this past year to sign several new pharmaceutical research alliances. Our team believes that the continued improvement in our systems approach will address many of the challenges faced by drug companies today. These challenges include understanding disease pathways, identifying a drug's mechanism of action, predicting toxicity and validating animal models." The session at BIO will be chaired by Beyond Genomics' Chief Technology Officer, Stephen Naylor, PhD. The speakers, all industry leaders, include: Leroy Hood Leroy Hood is an American biologist. He won the 2003 Lemelson-MIT Prize for inventing "four instruments that have unlocked much of the mystery of human biology" by helping decode the genome. , PhD, founder and President of the Institute for Systems Biology The Institute for Systems Biology (ISB) is a non-profit research institution, located in Seattle, Washington, United States. Leroy Hood co-founded the Institute with Alan Aderem and Ruedi Aebersold in 2000. in Seattle, Washington  This page is protected from moves until disputes have been resolved on the .The reason for its protection is listed on the protection policy page. ; David Lester, PhD, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Site Head, World Wide Clinical Technologies, from Pfizer, Inc.; Michael French, Senior Vice President, from Entelos, Inc. in Foster City, California
The session speakers will discuss the scientific disciplines of Systems Biology, specifics on the utility of in-silico modelling, and share perspectives on how major pharmaceutical companies can integrate Systems Biology into drug discovery and development programs. BG will outline its comprehensive approach, including the value of integrating analytical bench studies using sophisticated bioinformatic approaches. Beyond Genomics will also participate in the Partnering Sessions at BIO's Business Forum 2003 during the course of the convention. About Beyond Genomics Beyond Genomics is the first company to apply Systems Biology to drug discovery. BG's Product Focused Research approach leverages its proprietary technology to rapidly analyze clinically relevant samples such as tissue and body fluids. BG integrates data at the gene, protein, and metabolite metabolite, organic compound that is a starting material in, an intermediate in, or an end product of metabolism. Starting materials are substances, usually small and of simple structure, absorbed by the organism as food. levels to create new knowledge of disease pathways and drug response. BG performs its disease-specific research and development both independently and in partnership with pharmaceutical companies and leading academic institutions. The Company is committed to the success of its partnerships, and believes that Systems Biology will provide its partners with valuable knowledge for pharmaceutical discovery. BG's current research is focused on Central Nervous System diseases including Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , and cardiovascular diseases including atherosclerosis, as well as cancer and metabolic disorders. For more information, please visit www.BeyondGenomics.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion